AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23051744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23051744 — intervention group
Group type: COMPARATOR
Intervention: KRG and placebo
Number of subjects: 28
Study 20801749 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational intervention and periodic follow‐up contacts (BIC)
Number of subjects: 1867
Study 20801749 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 1867
Study 19759838 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS (20 minutes, 10 Hz, 10 seconds-ON, 20 seconds-OFF for a total of 4000 pulses)
Number of subjects: 20
Study 19759838 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 20
Study 19759838 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS
Number of subjects: 20
Study 15715969 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 100 mg, single dose
Number of subjects: 27
Study 15715969 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 200 mg, single dose
Number of subjects: 27
Study 15715969 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 400 mg, single dose
Number of subjects: 27
Study 15715969 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 27
Study 14609883 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine, 5 to 20 mg/d
Number of subjects: 833
Study 14609883 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine-fluoxetine combination, 6 and 25, 6 and 50, or 12 and 50 mg/d
Number of subjects: 833
Study 14609883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 833
Study 14609883 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine vs Placebo
Number of subjects: 833
Study 14609883 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine-fluoxetine vs Olanzapine
Number of subjects: 833
Study 14609883 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent mania
Number of subjects: 833
Study 14609883 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events for olanzapine-fluoxetine
Number of subjects: 833
Study 10805798 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (highly active antiretroviral therapy)
Number of subjects: 73
Study 8825804 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprepared solid foods (including egg yolk) in addition to breast milk starting at 4 months (n = 91)
Number of subjects: 141
Study 8825804 — intervention group
Group type: COMPARATOR
Intervention: Exclusively breast-fed (EBF) infants (n = 50)
Number of subjects: 141
Study 8825804 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 infants with the highest protein intakes (solid foods) matched to 20 EBF infants
Number of subjects: 141
Study 8825804 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 infants with the lowest protein intakes (EBF) matched to 20 infants given solid foods
Number of subjects: 141
Study 1375598 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic porcine galanin (0.5 mg in 100 mL saline)
Number of subjects: 13
Study 1375598 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (100 mL saline)
Number of subjects: 13
Study 3893700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine cream 1%
Number of subjects: 0
Study 3893700 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 0
Study 3893700 — intervention group
Group type: COMPARATOR
Intervention: 1% Clotrimazole cream
Number of subjects: 0
Study 31142044 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg-Zn/day
Number of subjects: 71
Study 31142044 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg-Zn/day
Number of subjects: 71
Study 31142044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 28991918 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid test-and-treat strategy plus Lactobacillus reuteri DSM 17938
Number of subjects: 76
Study 28991918 — intervention group
Group type: COMPARATOR
Intervention: No stool testing and placebo treatment
Number of subjects: 76
Study 25620670 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) measurement
Number of subjects: 135
Study 25620670 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up treatment after endoscopic recurrence
Number of subjects: 135
Study 25620670 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic analysis (Rutgeerts score)
Number of subjects: 135
Study 23521325 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 100 mg
Number of subjects: 686
Study 23521325 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 100/200 mg
Number of subjects: 686
Study 23521325 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Number of subjects: 686
Study 21802314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tris-acryl microspheres
Number of subjects: 56
Study 21802314 — intervention group
Group type: COMPARATOR
Intervention: PVA microspheres
Number of subjects: 56
Study 19221810 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive cantilever RBFPD
Number of subjects: 42
Study 19221810 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal invasive cantilever RBFPD
Number of subjects: 42
Study 19221810 — intervention group
Group type: COMPARATOR
Intervention: Two-retainer RBFPD (control)
Number of subjects: 42
Study 16443885 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 145
Study 16443885 — intervention group
Group type: EXPERIMENTAL
Intervention: glyburide
Number of subjects: 145
Study 15262624 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision during acquisition phase
Number of subjects: 20
Study 15262624 — intervention group
Group type: EXPERIMENTAL
Intervention: No vision after 560 trials of practice
Number of subjects: 20
Study 11773989 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan 300 mg twice daily
Number of subjects: 136
Study 11773989 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 136
Study 11773989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 9924262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-carbohydrate test meal (0.5 g fat/kg body weight + 17 g carbohydrate as lactose)
Number of subjects: 0
Study 9924262 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-carbohydrate test meal (0.5 g fat/kg body weight + 136 g carbohydrate, 60 g sucrose)
Number of subjects: 0
Study 7995896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lang stereotest
Number of subjects: 183
Study 7995896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lang stereotest combined with Snellen acuity
Number of subjects: 183
Study 7995896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lang stereotest combined with refractive error
Number of subjects: 183
Study 7995896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lang stereotest (subgroup of 17 multiply handicapped children)
Number of subjects: 183
Study 7995896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lang stereotest (test/retest reliability subgroup of 27 children)
Number of subjects: 183
Study 3354490 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (25% of calories)
Number of subjects: 6
Study 3354490 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (46% of calories)
Number of subjects: 6
Study 29652551 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 mg of fish-derived n-3 eicosapentaenoic and docosahexaenoic acids
Number of subjects: 349
Study 29652551 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 349
Study 28912192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical cervical ripening with Cervical Ripening Balloon (Cook-Medical Europe, Ireland) for 24 hours
Number of subjects: 1220
Study 28912192 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological cervical ripening with Propess system (10 mg of dinoprostone, Ferring SAS, France) before oxytocin administration
Number of subjects: 1220
Study 26571898 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at left Hegu (LI 4)
Number of subjects: 80
Study 26571898 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at right Hegu (LI 4)
Number of subjects: 80
Study 26571898 — intervention group
Group type: COMPARATOR
Intervention: Comparison between left‐acupoint group and right‐acupoint group
Number of subjects: 80
Study 26571898 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture feelings and MGH acupuncture sensation scale (MASS)
Number of subjects: 80
Study 23277105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation (PD)
Number of subjects: 176
Study 23277105 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Heller myotomy (LHM)
Number of subjects: 176
Study 21443600 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 40 mg after fasting (treatment A)
Number of subjects: 30
Study 21443600 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 40 mg after a standard breakfast (treatment B)
Number of subjects: 30
Study 21443600 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin with food
Number of subjects: 30
Study 19563951 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 600 mg once daily for 3 days and then 600 mg once weekly for 15 weeks
Number of subjects: 247
Study 19563951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 19563951 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 247
Study 19563951 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of statins and acetylsalicylic acid (ASA)
Number of subjects: 247
Study 17147908 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral agents (specifically aciclovir)
Number of subjects: 0
Study 17147908 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral agents for post-exposure prophylaxis
Number of subjects: 0
Study 15301652 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with delusions (no alternative explanation)
Number of subjects: 100
Study 15301652 — intervention group
Group type: COMPARATOR
Intervention: Patients with delusions (with alternative explanation)
Number of subjects: 100
Study 15301652 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with delusions (doubt in delusion, no alternative explanation)
Number of subjects: 100
Study 11198059 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 0
Study 11198059 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 0
Study 11198059 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0
Study 9062617 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg kg‐1 for induction of anaesthesia
Number of subjects: 8
Study 9062617 — intervention group
Group type: COMPARATOR
Intervention: thiopentone
Number of subjects: 8
Study 8400493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 8400493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 146
Study 8400493 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 50 mg 4 times daily
Number of subjects: 146
Study 8400493 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO 500 mg 4 times daily
Number of subjects: 146
Study 2956140 — intervention group
Group type: EXPERIMENTAL
Intervention: Rado-Salil ointment
Number of subjects: 40
Study 2956140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29807669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 65
Study 29807669 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 65
Study 27296091 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and omega-3 fatty acid supplements
Number of subjects: 423403
Study 27296091 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 423403
Study 24718930 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 11
Study 24718930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 22639959 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib plus low dose cytarabine (LDAC)
Number of subjects: 65
Study 22639959 — intervention group
Group type: COMPARATOR
Intervention: Low dose cytarabine (LDAC)
Number of subjects: 65
Study 20437026 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Central Retinal Arteriole Equivalent (CRAE)
Number of subjects: 234
Study 20437026 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CRAE
Number of subjects: 234
Study 20437026 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in Central Retinal Venule Equivalent (CRVE)
Number of subjects: 234
Study 20437026 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRAE or CRVE or changes in these diameters
Number of subjects: 234
Study 19153547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vastus medialis muscle in children with lateral patellar instability
Number of subjects: 56
Study 19153547 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 56
Study 17024944 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (SB)
Number of subjects: 35
Study 17024944 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional layer of Single Bond (SB)
Number of subjects: 35
Study 17024944 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐purpose (SMP) adhesive applied over SB
Number of subjects: 35
Study 17024944 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CE)
Number of subjects: 35
Study 17024944 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional layer of Clearfil SE Bond (CE)
Number of subjects: 35
Study 17024944 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt (AP)
Number of subjects: 35
Study 17024944 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional layer of Adper Prompt (AP)
Number of subjects: 35
Study 15611806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucus clearance device (MCD)
Number of subjects: 15
Study 15611806 — intervention group
Group type: COMPARATOR
Intervention: Sham mucus clearance device (SMCD)
Number of subjects: 15
Study 10791110 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP concentrations in nasopharyngeal secretions in asthmatic children
Number of subjects: 53
Study 10791110 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP concentrations in nasopharyngeal secretions in children with virus-induced wheezing
Number of subjects: 53
Study 10791110 — intervention group
Group type: COMPARATOR
Intervention: ECP levels in serum among subjects
Number of subjects: 53
Study 9069487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron
Number of subjects: 20
Study 9069487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8369232 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 900 mg to 1800 mg per day, stepwise increase over 12 months
Number of subjects: 20
Study 8369232 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphenadrine 300 mg per day
Number of subjects: 20
Study 8369232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3465027 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 80
Study 3465027 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 80
Study 31187168 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle albumin-bound paclitaxel (nab-ptx) used every week
Number of subjects: 0
Study 31187168 — intervention group
Group type: COMPARATOR
Intervention: Solvent-based paclitaxel used every week
Number of subjects: 0
Study 27612310 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention (1-hour sessions, 3-5 subjects, twice a week for 12 weeks)
Number of subjects: 60
Study 27612310 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal intervention (20-minute sessions, one staff member per participant, twice a week for 12 weeks)
Number of subjects: 60
Study 27612310 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 26224825 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Kirschner wire (K-wire) fixation
Number of subjects: 460
Study 26224825 — intervention group
Group type: COMPARATOR
Intervention: Volar locking-plate fixation
Number of subjects: 460
Study 24455059 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine (epinephrine 1:100,000)
Number of subjects: 36
Study 24455059 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (epinephrine 1:200,000)
Number of subjects: 36
Study 20195788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie carbohydrate-restricted diet (RD)
Number of subjects: 19
Study 20195788 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-calorie diet (CD)
Number of subjects: 19
Study 19176895 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks)
Number of subjects: 0
Study 19176895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19176895 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 17377162 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation and treatment options for intermittent claudication, including potential revascularization.
Number of subjects: 1
Study 15592331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 3 days
Number of subjects: 10
Study 15592331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11380714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine gel (topical application for 30 minutes)
Number of subjects: 40
Study 11380714 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (topical application for 30 minutes)
Number of subjects: 40
Study 9415510 — intervention group
Group type: EXPERIMENTAL
Intervention: Afferent A beta-fiber function (A beta-polyneuropathy)
Number of subjects: 34
Study 9415510 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairment of vibration sense (A beta-fiber function)
Number of subjects: 34
Study 9415510 — intervention group
Group type: COMPARATOR
Intervention: Nociceptive C-fiber function
Number of subjects: 34
Study 9415510 — intervention group
Group type: COMPARATOR
Intervention: Parasympathetic small fiber function
Number of subjects: 34
Study 9415510 — intervention group
Group type: COMPARATOR
Intervention: Acute zoster pain intensity
Number of subjects: 34
Study 8516087 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol beclomethasone dipropionate (BDP), 84 micrograms four times a day
Number of subjects: 195
Study 8516087 — intervention group
Group type: COMPARATOR
Intervention: Sustained‐release theophylline administered twice daily
Number of subjects: 195
Study 3521784 — intervention group
Group type: EXPERIMENTAL
Intervention: Razoxane (postoperative, continuous, long-term)
Number of subjects: 272
Study 3521784 — intervention group
Group type: COMPARATOR
Intervention: Control (identical clinical care, no adjuvant chemotherapy)
Number of subjects: 272
Study 3521784 — intervention group
Group type: EXPERIMENTAL
Intervention: Razoxane
Number of subjects: 272
Study 20604720 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg urapidil
Number of subjects: 132
Study 20604720 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg tamsulosin
Number of subjects: 132
Study 20604720 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg naftopidil
Number of subjects: 132
Study 20604720 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (240 mg flopropione and 1350 mg extract of Quercus salicina Blume/Quercus stenophylla Makino)
Number of subjects: 132
Study 31948091 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/leucovorin and oxaliplatin ± bevacizumab
Number of subjects: 182
Study 31109906 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs prescribed in 157 (87%) participants, median of 1 (IQR 1-2) antihypertensive medication.
Number of subjects: 181
Study 31109906 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of antihypertensives.
Number of subjects: 181
Study 31109906 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse health events during follow-up.
Number of subjects: 181
Study 28870194 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiCor fermentate
Number of subjects: 80
Study 28870194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26308286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (TA) injection
Number of subjects: 50
Study 26308286 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 50
Study 23128450 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 whole eggs per day (EGG)
Number of subjects: 37
Study 23128450 — intervention group
Group type: COMPARATOR
Intervention: Yolk-free egg substitute (SUB)
Number of subjects: 37
Study 21736666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting during Ramadan (≥10 fasting days)
Number of subjects: 72
Study 21736666 — intervention group
Group type: COMPARATOR
Intervention: Non-fasting control group
Number of subjects: 72
Study 19141433 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized SMS and MMS messages sent 2-5 times daily, printed materials, and brief monthly phone calls from a health counselor.
Number of subjects: 75
Study 19141433 — intervention group
Group type: COMPARATOR
Intervention: Monthly printed materials about weight control.
Number of subjects: 75
Study 16785054 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol amendment
Number of subjects: 154
Study 16785054 — intervention group
Group type: COMPARATOR
Intervention: Before protocol amendment
Number of subjects: 154
Study 16785054 — intervention group
Group type: EXPERIMENTAL
Intervention: After protocol amendment
Number of subjects: 154
Study 12871894 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg
Number of subjects: 109
Study 12871894 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 1.25 mg
Number of subjects: 109
Study 12871894 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol 2 mg plus norethisterone acetate 1 mg (E2 + NETA)
Number of subjects: 109